Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

[1]  T. Graeber,et al.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.

[2]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[3]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[4]  J. Whitfield,et al.  Strategies to Inhibit Myc and Their Clinical Applicability , 2017, Front. Cell Dev. Biol..

[5]  B. Haendler,et al.  Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents , 2016, Cell Death and Disease.

[6]  Sarah C. Ayling,et al.  The Ensembl gene annotation system , 2016, Database J. Biol. Databases Curation.

[7]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[8]  Laura M. Heiser,et al.  Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor , 2016, Oncotarget.

[9]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[10]  Clifford A. Meyer,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[11]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[12]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[13]  E. Prochownik,et al.  Small-molecule inhibitors of the Myc oncoprotein. , 2015, Biochimica et biophysica acta.

[14]  J. Licht,et al.  GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1 , 2015, Scientific Reports.

[15]  B. Stack,et al.  BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. , 2014, Cancer research.

[16]  A. Zoubeidi,et al.  PD-L1 is highly expressed in Enzalutamide resistant prostate cancer , 2014, Oncotarget.

[17]  J. Schug,et al.  Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia , 2014, Proceedings of the National Academy of Sciences.

[18]  M. McKeown,et al.  Therapeutic strategies to inhibit MYC. , 2014, Cold Spring Harbor perspectives in medicine.

[19]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[20]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[21]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[22]  Daniel Bottomly,et al.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation , 2013, PloS one.

[23]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[24]  Shwu‐Yuan Wu,et al.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.

[25]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[26]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[27]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[28]  Jennifer A. Smith,et al.  The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.

[29]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[30]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[31]  Angela N Koehler,et al.  A complex task? Direct modulation of transcription factors with small molecules. , 2010, Current opinion in chemical biology.

[32]  S. Salzberg,et al.  Transcript assembly and abundance estimation from RNA-Seq reveals thousands of new transcripts and switching among isoforms , 2010, Nature biotechnology.

[33]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[34]  L. Pachter,et al.  TopHat: discovering splice junctions with RNA-Seq , 2009, Bioinform..

[35]  M. Gleave,et al.  In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors , 2009, Clinical Cancer Research.

[36]  M. Dai,et al.  Inhibition of c‐Myc activity by ribosomal protein L11 , 2007, The EMBO journal.

[37]  A. C. Williams,et al.  Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia , 2007, Nature Cell Biology.

[38]  Adam A. Margolin,et al.  NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth , 2006, Proceedings of the National Academy of Sciences.

[39]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[40]  Weiqun Peng,et al.  Spatial clustering for identification of ChIP-enriched regions (SICER) to map regions of histone methylation patterns in embryonic stem cells. , 2014, Methods in molecular biology.

[41]  H. Drexler,et al.  Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. , 2011, Methods in molecular biology.

[42]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .